DRKS00021284已完成1 期
A placebo-controlled, randomized, double-blind trial to investigate the impact of dapagliflozin on the development of diabetic ketoacidosis and intermediate metabolism in type 1 diabetes using a dual stable tracer method: A safety study investigating the fuel shift theory in the human model - AZ02_Dapa_T1D
Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Abteilung für Endokrinologie und Diabetologie0 个研究点目标入组 17 人开始时间: 2020年4月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •Men aged 18-55 years (both inclusive) at the time of signing the consent form
- •Diagnosis of type 1 diabetes mellitus.
- •C-peptide (fasting value) = 0.07 ng/ml (= 0.02 nmol/L).
- •Stable insulin therapy for at least 6 months prior to screening by continuous subcutaneous insulin infusion (CSII).
- •Body Mass Index (BMI) between 20.0 and 35.0 kg/m2 (both inclusive)
- •HbA1c = 85,8 mmol/mol (= 10,0 %).
排除标准
- •People with muscular symptoms of hyperglycemia (tingling, pain). Known or suspected hypersensitivity to experimental products or other related products. History of severe allergy to medicines or foods or a history of severe anaphylactic reactions.
- •Presence of clinically relevant respiratory, cardiovascular, endocrine (except those related to diabetes mellitus), severe liver dysfunction, or other conditions that the investigator deems could compromise safety or compliance with the protocol. Receipt of an investigational medicinal product (IMP) within one month (or 5 half-life periods, whichever is longer) prior to screening. Uncontrolled hypertension is defined as blood pressure at screening (after 5 min rest) outside the range 90-160 mmHg for systolic or 50-100 mmHg for diastolic. Acute symptomatic (according to the investigator's assessment) urinary tract or genital infection, chronic or recurrent (= 3-year episodes) cystitis. Proliferative retinopathy or maculopathy (requiring treatment) and/or severe neuropathy, especially autonomic neuropathy, as determined by the investigator. Use of medications that may interfere with the interpretation of study results or are known to cause clinically relevant disturbances in insulin action, glucose utilization, or recovery from hypoglycemia (in the investigator's judgment). Hemoglobin < 12.5 g/dl, serum creatinine level = 1.43 mg/dl (= 126 µmol/L) (male), alanine transaminase (ALT) or alkaline phosphatase (ALP) > 2.5 x ULN. Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m². Positive laboratory result for screening test for HIV, hepatitis B and/or hepatitis C. Surgery or trauma with significant blood loss (more than 500 mL) within the last 3 months before screening. Smoker (defined as a subject who smokes at least five cigarettes or the equivalent product per day) who is unable or unwilling to refrain from smoking or from using nicotine gum or transdermal nicotine patches during the inpatient period Known or suspected alcohol or drug/chemical abuse (as determined by the investigator) or positive result of an alcohol test or positive result of a drug abuse test.
研究者
相似试验
尚未招募
4 期
A placebo-controlled, randomized, double-blind trial of the effects of modified release 4-aminopyridine on upper limb impairment in Multiple SclerosisNeurological - Multiple sclerosisMultiple SclerosisACTRN12613000331730Austin Health60
进行中（未招募）
1 期
A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusActive eosinophilic esophagitisMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-000082-16-PLEsoCap AG42
进行中（未招募）
4 期
Can treatment with Cerebrolysin improve recovery after acute ischemic stroke?Radiologically confirmed acute ischemic stroke with onset within 72 hours prior to screeningCirculatory SystemAcute ischemic strokeISRCTN88122184The foundation for the study of neuroscience and neuroregeneration290
进行中（未招募）
1 期
A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusActive eosinophilic esophagitisMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-000082-16-NLEsoCap AG42
招募中
2 期
A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitischronic inflammation of the esophagus10017969eosinophilic esophagitisNL-OMON52665EsoCap AG10